These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17878523)

  • 1. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
    Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
    Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene signature-based prediction of tumor response to cyclophosphamide.
    Korrat A; Greiner T; Maurer M; Metz T; Fiebig HH
    Cancer Genomics Proteomics; 2007; 4(3):187-95. PubMed ID: 17878522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
    Bruheim S; Xi Y; Ju J; Fodstad O
    Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice.
    Sugawara M; Okamoto K; Kadowaki T; Kusano K; Fukamizu A; Yoshimura T
    Drug Metab Dispos; 2010 Mar; 38(3):526-33. PubMed ID: 20007293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of VDR-responsive gene signatures in breast cancer cells.
    Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
    Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.
    De Angelis PM; Kravik KL; Tunheim SH; Haug T; Reichelt WH
    Mol Cancer; 2004 Apr; 3():11. PubMed ID: 15109396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer.
    Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T
    Cancer Genomics Proteomics; 2011; 8(2):87-92. PubMed ID: 21471518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.
    Los G; Benbatoul K; Gately DP; Barton R; Christen R; Robbins KT; Vicario D; Kirmani S; Orloff LA; Weisman R; Howell SB
    Clin Cancer Res; 1999 Jul; 5(7):1610-8. PubMed ID: 10430059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
    Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
    Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.